Year: 2026
Type: article
Abstract: Dendritic Cell (DC)-based vaccine is a tumor immunotherapy approach with great potential, and improving the efficacy is an urgent problem to be solved. RIPK1 is an important regulator of inflammation and cell death, and may play a significant role in the tumor immune function of DCs. Our study found that DC-specific knockout of Ripk1 can inhibit tumor growth in mice by increasing DC immune infiltration and strengthening the interactions with cytotoxic T cells in the tumor microenvironment. The efficacy of DC-specific Ripk1 knockout was also validated in in vitro experiments, revealing the function of the Ripk1 knockout involved augment of antigen presentation capacity and activation status of DCs and their ability to activate Cd8 + T cells. Furthermore, this Ripk1 knocked DCs vaccine was employed to treat the tumor carry mice and it can effectively inhibit tumor growth compared with the wild type DCs vaccine. RIPK1 is expected to become a new target for improving the efficacy of DC vaccines.
Source: Cancer Immunology Immunotherapy
Authors: Lin Mao, Yangjing Ou, Yuchao Zhang, Minghui Wang, Guoqing Dong, Asma Khanniche, Hailong Wang, Zhenchuan Wu, Haibing Zhang, Landian Hu, Xiangyin Kong
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,590
Awards: G1827946989, G8912243550
OpenAlex ID: W7138178759